A controversial bill in Tennessee is causing a stir, and it's all about the future of pharmacies and their ownership. The battle lines are drawn between independent pharmacies and large corporations, with the latter threatening to close their doors if the bill passes.
The proposed legislation aims to prohibit pharmacy benefit managers (PBMs) from owning or controlling pharmacies in Tennessee. This has sparked a heated debate, with supporters arguing that it targets vertical integration and aims to protect independent pharmacies. Senator Bobby Harshbarger, the bill's sponsor, believes that such integration allows big corporations to favor their subsidiaries, putting smaller, independent pharmacies at a disadvantage.
However, companies like CVS Health, which owns PBMs and retail pharmacy chains, are strongly opposing the bill. They warn that if it becomes law, they may be forced to close all their pharmacy locations in Tennessee, a total of 134 stores. Amy Thibault, a spokesperson for CVS Health, explains that this would not only impact pharmacies but also their Minute Clinics, which provide essential medical services within their stores.
But here's where it gets controversial: CVS Health claims that the bill will lead to healthcare chaos, affecting not just their business but also patients' access to vital services. They argue that it will result in job losses and reduced access to specialty pharmacies and home delivery options for those with complex medical needs.
And this is the part most people miss: the legislation itself does not mandate pharmacy closures. Instead, it sets a deadline for PBM-affiliated pharmacies to divest or restructure their ownership by January 1st, 2027, with limited transition options available until the end of 2026.
Natalie Elliott Handy, a caregiver who relies on CVS Specialty care, shares her concerns. She believes the bill fails to protect individuals and caregivers, taking away a critical service that many depend on.
A fiscal analysis reveals an uncertain financial impact on the state. In the short term, there may be higher drug acquisition costs and administrative expenses as pharmacy networks adjust. But supporters argue that the bill could bring transparency and reduce practices like spread pricing, which was found in a 2024 audit of CVS Caremark.
Jake Standefer, from Access Pharmacy, supports the change, believing it gives patients more choice. He says it aims to break up monopolies by preventing those who set reimbursement rates from owning the pharmacies being reimbursed.
Healthcare providers like Dr. Johnetta Blakely have also testified, expressing concerns about patient care. She highlights how PBM practices can delay care, especially in oncology, where delays can have serious consequences.
As the bill moves to the Senate Finance, Ways, and Means Committee, the debate continues. The potential impact on patients, pharmacies, and the state's healthcare system remains a hot topic.
What do you think? Is this bill a necessary step to protect independent pharmacies and patient care, or does it risk causing more harm than good? We'd love to hear your thoughts in the comments!
